We welcome inquiries from the media, and encourage reporters, editors, bloggers and other journalists to contact us for information about our company and research programs at media@sarepta.com or 617.274.4052. For other inquiries, please visit our Contact Page.

 
 
 
 

QUICK FACTS

Sarepta Therapeutics is based in Cambridge, Massachusetts.

Our stock is listed on NASDAQ under the symbol “SRPT.”

Sarepta's business is focused on the discovery, development and commercialization of RNA-targeted therapies for rare and infectious diseases.

 
 

MEDIA RESOURCE CENTER

 
 

Archived Press Releases

 
04/27/17Download PDFSarepta Therapeutics Announces First Quarter 2017 Financial Results and Recent Corporate Developments
04/17/17Download PDFSarepta Therapeutics to Announce First Quarter 2017 Financial Results and Recent Corporate Developments on April 27, 2017
04/05/17Download PDFSarepta Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04/03/17Download PDFSarepta Therapeutics Announces Appointment of Catherine Stehman-Breen, M.D., M.S. as Chief Medical Officer
03/31/17Download PDFSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/30/17Download PDFSarepta Therapeutics Announces Addition of Kenneth Fischbeck, M.D. and Matthew Wood M.D., Ph.D. to the Company’s Strategic and Scientific Advisory Board
03/17/17 Sarepta Therapeutics Announces Presentations at the 2017 MDA Scientific Conference
03/02/17 Sarepta Therapeutics to Present Company Overview at the Cowen and Company 37th Annual Health Care Conference
02/28/17Download PDFSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/28/17Download PDFSarepta Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments
02/21/17 Sarepta Therapeutics Agrees to Sale of Priority Review Voucher for $125M
02/15/17 Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments on February 28, 2017
01/31/17Download PDFSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/10/17Download PDFSarepta Therapeutics Enters into License Agreement with Nationwide Children’s Hospital for Galgt2 Gene Therapy Program
01/10/17Download PDFSarepta Therapeutics Enters into Research Agreement and Option Agreement with Nationwide Children’s Hospital for Microdystrophin Gene Therapy Program
01/03/17Download PDFSarepta Therapeutics to Present Company Overview at the 2017 35th Annual J.P. Morgan Healthcare Conference



This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.